Trial Profile
A Phase 2 Study of AZD6244 in Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 07 Oct 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Mar 2014 Planned End Date changed from 1 Mar 2012 to 1 Mar 2015, as per ClinicalTrials.gov record.